A phase I study of HER1, HER2 dual kinase inhibitor lapatinib plus the proteasome inhibitor bortezomib in patients with advanced malignancies.
Filipa C LynceHongkun WangEmanuel F PetricoinPaula R PohlmannBrandon SmagloJimmy HwangAiwu R HeDeepa S SubramaniamJohn DeekenJohn MarshallMichael J PishvaianPublished in: Cancer chemotherapy and pharmacology (2019)
NCT01497626.
Keyphrases